# A Prospective Observational Study on Targeted Therapy for Unresectable or Metastatic BRAFV600E Mutant Melanoma Patients

> **NCT04911998** · — · COMPLETED · sponsor: **Pierre Fabre Medicament** · enrollment: 400 (actual)

## Conditions studied

- Melanoma (Skin)
- Metastatic Melanoma
- BRAF V600 Mutation

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT04911998
- **Lead sponsor:** Pierre Fabre Medicament
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-02-02
- **Primary completion:** 2024-03-29
- **Final completion:** 2024-03-29
- **Target enrollment:** 400 (ACTUAL)
- **Last updated:** 2026-01-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04911998

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04911998, "A Prospective Observational Study on Targeted Therapy for Unresectable or Metastatic BRAFV600E Mutant Melanoma Patients". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04911998. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*